The intranasal drug delivery devices market size has grown strongly in recent years. It will grow from $65.09 billion in 2025 to $70.77 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increasing prevalence of respiratory and nasal disorders, rising use of nasal route for systemic drug delivery, growth in self-administration drug devices, increasing approvals of intranasal therapies, expansion of outpatient treatment models.
The intranasal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $99.11 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing development of biologics and vaccines via nasal delivery, rising demand for homecare drug administration, expansion of intranasal delivery for neurological therapies, growing investments in advanced drug-device combinations, increasing focus on patient compliance solutions. Major trends in the forecast period include increasing adoption of precision nasal delivery systems, rising demand for non-invasive drug administration, growing development of multi-dose nasal devices, expansion of patient-friendly drug delivery formats, enhanced focus on rapid drug absorption.
The rising prevalence of chronic diseases is anticipated to drive the growth of the intranasal drug delivery devices market in the coming years. Chronic diseases are conditions that persist for one year or longer and require continuous medical care, limit daily activities, or both. Intranasal drug delivery devices are used in the management of chronic diseases by offering a non-invasive and effective method of medication administration. These devices enable drugs to be delivered directly to the targeted area, providing convenience, ease of use, and rapid absorption. For example, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the number of individuals in England at risk of developing type 2 diabetes increased to 3,615,330 from 3,066,330 in 2022, with more than half a million additional people (549,000) identified as having non-diabetic hyperglycemia, or pre-diabetes. Therefore, the growing prevalence of chronic diseases is fueling the expansion of the intranasal drug delivery devices market.
Major pharmaceutical companies in the nasal drug delivery technology market are actively engaged in developing new and improved products to offer innovative drug administration methods and maintain their market position. For instance, in January 2023, AptarGroup, Inc., a US-based drug delivery and pharmaceutical company, introduced APF Futurity, the first recyclable, metal-free, multidose nasal spray for delivering nasal saline and similar over-the-counter (OTC) formulations. This product, made from polyolefin materials and devoid of metal components or recycling disruptors, reduces the need for separation in recycling streams and supports a higher grade of recycled materials. Notably, APF Futurity is a highly recyclable nasal spray pump that has obtained Class AA certification from cyclos-HTP for recycling streams in Europe.
In January 2024, Kindeva Drug Delivery, a US-based provider of drug-device combination product development and manufacturing, acquired Summit Biosciences Inc. for an undisclosed amount. Through this acquisition, Kindeva seeks to enhance its drug-delivery platform by incorporating specialized intranasal formulation and manufacturing capabilities, allowing it to support biopharma clients across a wider range of complex combination products. Summit Biosciences Inc. is a US-based contract development and manufacturing organization specializing in intranasal drug-delivery solutions.
Major companies operating in the intranasal drug delivery devices market are Johnson and Johnson Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline Plc, 3M Company, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., AptarGroup Inc., West Pharmaceutical Services Inc., Recipharm AB, Nemera Development S.A., Consort Medical plc., Vectura Group plc., OptiNoset Inc., Flamel Technologies, Aegis Therapeutics LLC, PendoPharm Inc., Kurve Technology Inc., Impel NeuroPharma, Impexium Medical Products, ENT Technologies Pty. Ltd., Neurelis Inc.
North America was the largest region in the intranasal drug delivery devices market in 2025. The regions covered in the intranasal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intranasal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the intranasal drug delivery devices market by increasing costs of imported polymers, precision plastic components, metered-dose mechanisms, and pharmaceutical-grade materials used in sprays, inhalers, and nasal devices. Manufacturers in North America and Europe are particularly affected due to reliance on specialized imported components, while Asia-Pacific faces cost pressures on device exports. These tariffs are raising production costs and extending development timelines. However, they are also encouraging localized device manufacturing, regional supplier diversification, and investments in cost-optimized nasal delivery technologies.
The intranasal drug delivery devices market research report is one of a series of new reports that provides intranasal drug delivery devices market statistics, including intranasal drug delivery devices industry global market size, regional shares, competitors with a intranasal drug delivery devices market share, detailed intranasal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the intranasal drug delivery devices industry. This intranasal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Intranasal drug delivery devices are medical instruments designed to administer medications into the nasal cavity. These devices are specifically created to deliver medications directly to the highly vascularized nasal mucosa, which boasts a substantial surface area, facilitating rapid absorption of the drug into the bloodstream. Intranasal drug delivery devices are capable of delivering drugs or therapeutic substances in various forms, including sprays, powders, or liquid solutions, directly into the nasal cavity.
The primary products within the realm of intranasal drug delivery devices include powder delivery devices, liquid delivery devices, pressurized metered-dose inhalers, and other related devices. Powder delivery devices, a subtype of medical or pharmaceutical devices, are designed for administering medications in unit-dose or multi-dose forms and find applications in various medical conditions such as chronic obstructive pulmonary disease (COPD), rhinitis, cystic fibrosis, nasal congestion, asthma, among others. The end users of these devices include hospitals, clinics, homecare, and other healthcare settings.
The intranasal drug delivery devices market consists of sales of nasal sprays, nasal powder devices, nasal antipsychotic medications, nasal epinephrine devices, nasal drops, and nasal inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The intranasal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $99.11 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing development of biologics and vaccines via nasal delivery, rising demand for homecare drug administration, expansion of intranasal delivery for neurological therapies, growing investments in advanced drug-device combinations, increasing focus on patient compliance solutions. Major trends in the forecast period include increasing adoption of precision nasal delivery systems, rising demand for non-invasive drug administration, growing development of multi-dose nasal devices, expansion of patient-friendly drug delivery formats, enhanced focus on rapid drug absorption.
The rising prevalence of chronic diseases is anticipated to drive the growth of the intranasal drug delivery devices market in the coming years. Chronic diseases are conditions that persist for one year or longer and require continuous medical care, limit daily activities, or both. Intranasal drug delivery devices are used in the management of chronic diseases by offering a non-invasive and effective method of medication administration. These devices enable drugs to be delivered directly to the targeted area, providing convenience, ease of use, and rapid absorption. For example, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the number of individuals in England at risk of developing type 2 diabetes increased to 3,615,330 from 3,066,330 in 2022, with more than half a million additional people (549,000) identified as having non-diabetic hyperglycemia, or pre-diabetes. Therefore, the growing prevalence of chronic diseases is fueling the expansion of the intranasal drug delivery devices market.
Major pharmaceutical companies in the nasal drug delivery technology market are actively engaged in developing new and improved products to offer innovative drug administration methods and maintain their market position. For instance, in January 2023, AptarGroup, Inc., a US-based drug delivery and pharmaceutical company, introduced APF Futurity, the first recyclable, metal-free, multidose nasal spray for delivering nasal saline and similar over-the-counter (OTC) formulations. This product, made from polyolefin materials and devoid of metal components or recycling disruptors, reduces the need for separation in recycling streams and supports a higher grade of recycled materials. Notably, APF Futurity is a highly recyclable nasal spray pump that has obtained Class AA certification from cyclos-HTP for recycling streams in Europe.
In January 2024, Kindeva Drug Delivery, a US-based provider of drug-device combination product development and manufacturing, acquired Summit Biosciences Inc. for an undisclosed amount. Through this acquisition, Kindeva seeks to enhance its drug-delivery platform by incorporating specialized intranasal formulation and manufacturing capabilities, allowing it to support biopharma clients across a wider range of complex combination products. Summit Biosciences Inc. is a US-based contract development and manufacturing organization specializing in intranasal drug-delivery solutions.
Major companies operating in the intranasal drug delivery devices market are Johnson and Johnson Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline Plc, 3M Company, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., AptarGroup Inc., West Pharmaceutical Services Inc., Recipharm AB, Nemera Development S.A., Consort Medical plc., Vectura Group plc., OptiNoset Inc., Flamel Technologies, Aegis Therapeutics LLC, PendoPharm Inc., Kurve Technology Inc., Impel NeuroPharma, Impexium Medical Products, ENT Technologies Pty. Ltd., Neurelis Inc.
North America was the largest region in the intranasal drug delivery devices market in 2025. The regions covered in the intranasal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intranasal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the intranasal drug delivery devices market by increasing costs of imported polymers, precision plastic components, metered-dose mechanisms, and pharmaceutical-grade materials used in sprays, inhalers, and nasal devices. Manufacturers in North America and Europe are particularly affected due to reliance on specialized imported components, while Asia-Pacific faces cost pressures on device exports. These tariffs are raising production costs and extending development timelines. However, they are also encouraging localized device manufacturing, regional supplier diversification, and investments in cost-optimized nasal delivery technologies.
The intranasal drug delivery devices market research report is one of a series of new reports that provides intranasal drug delivery devices market statistics, including intranasal drug delivery devices industry global market size, regional shares, competitors with a intranasal drug delivery devices market share, detailed intranasal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the intranasal drug delivery devices industry. This intranasal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Intranasal drug delivery devices are medical instruments designed to administer medications into the nasal cavity. These devices are specifically created to deliver medications directly to the highly vascularized nasal mucosa, which boasts a substantial surface area, facilitating rapid absorption of the drug into the bloodstream. Intranasal drug delivery devices are capable of delivering drugs or therapeutic substances in various forms, including sprays, powders, or liquid solutions, directly into the nasal cavity.
The primary products within the realm of intranasal drug delivery devices include powder delivery devices, liquid delivery devices, pressurized metered-dose inhalers, and other related devices. Powder delivery devices, a subtype of medical or pharmaceutical devices, are designed for administering medications in unit-dose or multi-dose forms and find applications in various medical conditions such as chronic obstructive pulmonary disease (COPD), rhinitis, cystic fibrosis, nasal congestion, asthma, among others. The end users of these devices include hospitals, clinics, homecare, and other healthcare settings.
The intranasal drug delivery devices market consists of sales of nasal sprays, nasal powder devices, nasal antipsychotic medications, nasal epinephrine devices, nasal drops, and nasal inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Intranasal Drug Delivery Devices Market Characteristics
3. Intranasal Drug Delivery Devices Market Supply Chain Analysis
4. Global Intranasal Drug Delivery Devices Market Trends and Strategies
5. Intranasal Drug Delivery Devices Market Analysis of End Use Industries
7. Global Intranasal Drug Delivery Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Intranasal Drug Delivery Devices Total Addressable Market (TAM) Analysis for the Market
9. Intranasal Drug Delivery Devices Market Segmentation
10. Intranasal Drug Delivery Devices Market Regional and Country Analysis
11. Asia-Pacific Intranasal Drug Delivery Devices Market
12. China Intranasal Drug Delivery Devices Market
13. India Intranasal Drug Delivery Devices Market
14. Japan Intranasal Drug Delivery Devices Market
15. Australia Intranasal Drug Delivery Devices Market
16. Indonesia Intranasal Drug Delivery Devices Market
17. South Korea Intranasal Drug Delivery Devices Market
18. Taiwan Intranasal Drug Delivery Devices Market
19. South East Asia Intranasal Drug Delivery Devices Market
20. Western Europe Intranasal Drug Delivery Devices Market
21. UK Intranasal Drug Delivery Devices Market
22. Germany Intranasal Drug Delivery Devices Market
23. France Intranasal Drug Delivery Devices Market
24. Italy Intranasal Drug Delivery Devices Market
25. Spain Intranasal Drug Delivery Devices Market
26. Eastern Europe Intranasal Drug Delivery Devices Market
27. Russia Intranasal Drug Delivery Devices Market
28. North America Intranasal Drug Delivery Devices Market
29. USA Intranasal Drug Delivery Devices Market
30. Canada Intranasal Drug Delivery Devices Market
31. South America Intranasal Drug Delivery Devices Market
32. Brazil Intranasal Drug Delivery Devices Market
33. Middle East Intranasal Drug Delivery Devices Market
34. Africa Intranasal Drug Delivery Devices Market
36. Intranasal Drug Delivery Devices Market Competitive Landscape and Company Profiles
37. Intranasal Drug Delivery Devices Market Other Major and Innovative Companies
40. Intranasal Drug Delivery Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Intranasal Drug Delivery Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses intranasal drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for intranasal drug delivery devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The intranasal drug delivery devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Powder Delivery Device; Liquid Delivery Device; Pressurized Metered-Dose Inhalers; Other Products2) By Dosage: Unit-Dose; Multi-Dose
3) By Application: Chronic Obstructive Pulmonary Disease (COPD); Rhinitis; Cystic Fibrosis; Nasal Congestion; Asthma; Other Applications
4) By End User: Hospitals; Clinics; Homecare; Other End Users
Subsegments:
1) By Powder Delivery Device: Single-Dose Powder Device; Multi-Dose Powder Device2) By Liquid Delivery Device: Single-Dose Liquid Device; Multi-Dose Liquid Device
3) By Pressurized Metered-Dose Inhalers (pMDIs): Breath-Actuated PMDIs; Conventional pMDIs
4) By Other Products: Gel Delivery Device; Nebulizers; Nasal Sprays
Companies Mentioned: Johnson and Johnson Inc.; Novartis AG; AstraZeneca plc.; GlaxoSmithKline Plc; 3M Company; Becton Dickinson and Company; Teva Pharmaceutical Industries Ltd.; AptarGroup Inc.; West Pharmaceutical Services Inc.; Recipharm AB; Nemera Development S.A.; Consort Medical plc.; Vectura Group plc.; OptiNoset Inc.; Flamel Technologies; Aegis Therapeutics LLC; PendoPharm Inc.; Kurve Technology Inc.; Impel NeuroPharma; Impexium Medical Products; ENT Technologies Pty. Ltd.; Neurelis Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Intranasal Drug Delivery Devices market report include:- Johnson and Johnson Inc.
- Novartis AG
- AstraZeneca plc.
- GlaxoSmithKline Plc
- 3M Company
- Becton Dickinson and Company
- Teva Pharmaceutical Industries Ltd.
- AptarGroup Inc.
- West Pharmaceutical Services Inc.
- Recipharm AB
- Nemera Development S.A.
- Consort Medical plc.
- Vectura Group plc.
- OptiNoset Inc.
- Flamel Technologies
- Aegis Therapeutics LLC
- PendoPharm Inc.
- Kurve Technology Inc.
- Impel NeuroPharma
- Impexium Medical Products
- ENT Technologies Pty. Ltd.
- Neurelis Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 70.77 Billion |
| Forecasted Market Value ( USD | $ 99.11 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
